GNFT - MGL-3196: Not Ideal But Currently The Best

Madrigal Pharmaceuticals (MDGL) is a US biotech company that currently has only one drug, MGL-3196, under clinical investigation stage. Being Madrigal’s key asset, MGL-3196 has proven its strong potential in Non-Alcoholic Steatohepatitis ((NASH)) and is currently advancing to Phase III.

Non-Alcoholic Steatohepatitis ((NASH)) is a disease that affects a lot of people worldwide yet no FDA approved drug ever exists. It currently affects about 8% of the entire US population and is estimated to exceed a $20~30B market size in 2026 globally. It’s a more aggressive form of Non-Alcoholic Fatty Liver Disease (NAFLD)